Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 31Advanced Solid Tumors 25Advanced Solid Tumor 24Carcinoma, Non-Small-Cell Lung 19Neoplasms 15Solid Tumor 12Prostatic Neoplasms 12Multiple Myeloma 11Pancreatic Neoplasms 10Neoplasm Metastasis 10Small Cell Lung Carcinoma 9Recurrence 9Ovarian Neoplasms 9Lung Neoplasms 9Stomach Neoplasms 8Melanoma 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Sarcoma 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Solid Tumors 6Carcinoma, Transitional Cell 5Advanced Solid Tumour 5Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma 4

Interventions

Etoposide 3Carboplatin 3atezolizumab 2tislelizumab 1obinutuzumab 1lutetium Lu 177 dotatate 1Paclitaxel 1Injections 1EC regimen 1Drug Therapy 1Cisplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Extensive Stage Small Cell Lung Cancer × Injections × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡